Mehlika Dilek ALTINTOP, Ahmet ÖZDEMİR, Belgin Sever, Gülşen AKALIN Çİ

Design, synthesis and in vitro evaluation of new thiosemicarbazone derivatives as potential anticancer agents

Thiosemicarbazones play a pivotal role as potential therapeutic agents for the management of lung cancer. 4-(4-Cyanophenyl)-1-[(5-arylfuran-2-yl)methylene]thiosemicarbazides (1-10) were obtained via the reaction of 4-(4cyanophenyl)thiosemicarbazide with 5-arylfurfurals. MTT assay was performed to assess their cytotoxic effects on A549 human lung adenocarcinoma and L929 mouse fibroblast cell lines. Compounds 1, 5, 6 and 7 were identified as the most effective anticancer agents on A549 cell line with IC50 values of 12.75±0.35 µg/mL, 4.30±0.61 µg/mL, 5.50±2.12 µg/mL and 5.90±0.57 µg/mL, respectively compared to cisplatin (IC50= 12.00±0.71 µg/mL). The IC50 values of these compounds for L929 cell line were higher than their IC50 values for A549 cell line indicating that their anticancer effects were selective. The apoptotic effects of these compounds were also analyzed based on Annexin V-PI binding capacities in flow cytometry. According to flow cytometric analyses, the early apoptotic effects of compounds 1, 5, 6 and 7 on A549 cell line were determined as 4.7, 5.1, 7.3 and 5.1%, whereas their late apoptotic effects were determined as 3.7, 2.0, 4.9 and 3.3%, respectively. Compound 6 showed more apoptotic activity than compounds 1, 5 and 7. According to these findings, compounds 5 and 6 stand out as promising anticancer agents for further in vitro and in vivo studies.

PDF

___

Wood SL, Pernemalm M, Crosbie PA, Whetton AD. Molecular histology of lung cancer: from targets to treatments. Cancer Treat Rev. 2015; 41(4): 361-375. [CrossRef]
Gyoba J, Shan S, Roa W, Bédard ELR. Diagnosing lung cancers through examination of micro-RNA biomarkers in blood, plasma, serum and sputum: a review and summary of current literature. Int J Mol Sci. 2016; 17(4): 494. [CrossRef]
Li L, Zhu T, Gao Y-F, Zheng W, Wang C-J, Xiao L, Huang MS, Yin JY, Zhou HH, Liu ZQ. Targeting DNA damage response in the radio(chemo)therapy of non-small cell lung cancer. Int J Mol Sci. 2016; 17(6): E839. [CrossRef]
Ansari J, Shackelford RE, El-Osta H. Epigenetics in non-small cell lung cancer: from basics to therapeutics. Transl Lung Cancer Res. 2016; 5(2): 155-171. [CrossRef]
Gavrilescu LC, Denkers EY. Apoptosis and the balance of homeostatic and pathologic responses to protozoan infection. Infect Immun. 2003; 71(11): 6109-6115. [CrossRef]
El-Khattouti A, Selimovic D, Haikel Y, Hassan M. Crosstalk between apoptosis and autophagy: molecular mechanisms and therapeutic strategies in cancer. J Cell Death. 2013; 6: 37-55. [CrossRef]
Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu H-Y, Lin L-T. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol. 2015; 35: S78-S103. [CrossRef]
Kamal A, Faazil S, Malik MS. Apoptosis-inducing agents: a patent review (2010 – 2013). Expert Opin Ther Pat. 2014; 24(3): 339-354. [CrossRef]
Wong RSY. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011; 30: 87. [CrossRef]
Pore MM, Hiltermann TJN, Kruyt FAE. Targeting apoptosis pathways in lung cancer. Cancer Lett. 2013; 332(2): 359368. [CrossRef]
Moorthy NSHN, Cerqueira NMFSA, Ramos MJ, Fernandes PA. Aryl- and heteroaryl-thiosemicarbazone derivatives and their metal complexes: a pharmacological template. Recent Pat Anti-Cancer Drug Discov. 2013; 8(2): 168-182. [CrossRef]
Yu Y, Kalinowski DS, Kovacevic Z, Siafakas AR, Jansson PJ, Stefani C, Lovejoy DB, Sharpe PC, Bernhardt PV, Richardson DR. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem. 2009; 52(17): 5271-5294. [CrossRef]
Kalinowski DS, Quach P, Richardson DR. Thiosemicarbazones: the new wave in cancer treatment. Future Med Chem. 2009; 1(6): 1143-1151. [CrossRef]
Mannargudi MB, Deb S. Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy? J Cancer Res Clin Oncol. 2017; 143(8): 1499-1529. [CrossRef]
Yee EMH, Brandl MB, Black DS, Vittorio O, Kumar N. Synthesis of isoflavene-thiosemicarbazone hybrids and evaluation of their anti-tumor activity. Bioorg Med Chem Lett. 2017; 27(11): 2454-2458. [CrossRef]
Wang Y, Gu W, Shan Y, Liu F, Xu X, Yang Y, Zhang Q, Zhang Y, Kuang H, Wang Z, Wang S. Design, synthesis and anticancer activity of novel nopinone-based thiosemicarbazone derivatives. Bioorg Med Chem Lett. 2017; 27: 23602363. [CrossRef]
Pape VFS, Tóth S, Füredi A, Szebényi K, Lovrics A, Szabó P, Wiese M, Szakács G. Design, synthesis and biological evaluation of thiosemicarbazones, hydrazinobenzothiazoles and arylhydrazones as anticancer agents with a potential to overcome multidrug resistance. Eur J Med Chem. 2016; 117: 335-354. [CrossRef]
Altıntop MD, Atlı Ö, Ilgın S, Demirel R, Özdemir A, Kaplancıklı ZA. Synthesis and biological evaluation of new naphthalene substituted thiosemicarbazone derivatives as potent antifungal and anticancer agents. Eur J Med Chem. 2016; 108: 406-414. [CrossRef]
Altıntop MD, Sever B, Özdemir A, Kuş G, Oztopcu-Vatan P, Kabadere S, Kaplancikli ZA. Synthesis and evaluation of naphthalene-based thiosemicarbazone derivatives as new anticancer agents against LNCaP prostate cancer cells. J Enzyme Inhib Med Chem. 2016; 31(3): 410-416. [CrossRef]
Altıntop MD, Temel HE, Sever B, Akalın Çiftçi G, Kaplancıklı ZA. Synthesis and evaluation of new benzodioxolebased thiosemicarbazone derivatives as potential antitumor agents. Molecules 2016; 21(11): E1598. [CrossRef]
Serra S, Moineaux L, Vancraeynest C, Masereel B, Wouters J, Pochet L, Frédérick R. Thiosemicarbazide, a fragment with promising indolamine-2,3-dioxygenase (IDO) inhibition properties. Eur J Med Chem. 2014; 82: 96-105. [CrossRef]
Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63. [CrossRef]
Zhou H-Y, Dong F-Q, Du X-L, Zhou Z-K, Huo H-R, Wang W-H, Zhan HD, Dai YF, Jing Meng, Sui YP, Li J, Sui F, Zhai YH. Antitumor activities of biscoumarin and dihydropyran derivatives. Bioorg Med Chem Lett. 2016; 26(16): 3876-3880. [CrossRef]